Genome editing, or gene editing, helps scientists make specific changes to the DNA of living organisms, like humans, animals, and plants. Gene editing is entering a new phase—one increasingly defined by clinical validation rather than promise.
For much of the past decade, the technology followed a familiar innovation curve: rapid excitement, bold projections, and, at times, inflated expectations. Today, that narrative is shifting. As explored in the William Blair Thinking Podcast episode "Biotech Breakthroughs: Gene Editing Moves Beyond the Hype," gene editing is moving beyond its early hype cycle and into a period of more tangible clinical progress.
A key inflection point has been the approval of the first ex vivo gene-editing therapy, which refers to treatments in which a patient’s cells are removed, genetically modified, and then returned to the patient. While early applications have been complex and highly specialized, they demonstrate that gene editing can move from concept to real-world treatment. These initial approvals are helping establish regulatory pathways and providing important proof points for the field.
At the same time, the technology itself is evolving rapidly. What began primarily with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a technology that identifies precise genomic locations and edits specific DNA sequences. CRISPR-based approaches are expanding into a broader set of tools, including base editing—which allows one DNA letter to change into another without breaking the DNA backbone—and other next-generation techniques designed to improve precision and control.
This progression reflects a broader maturation of the space. Rather than relying on a single breakthrough, gene editing is developing as a platform of complementary technologies, each suited to different therapeutic challenges. As a result, the opportunity sets may expand over time, from rare genetic diseases toward more complex conditions.
Looking ahead, upcoming clinical milestones will be important in shaping the next phase of development. Continued data will help determine not only which approaches are most effective, but also how scalable and durable these therapies may be.
Importantly, this evolution of gene editing is not only scientific. As more data emerges, the focus is increasingly on the durability of outcomes, safety, and delivery—factors that will play a critical role in long-term adoption.
Gene editing is no longer just a story of what could be possible. It’s increasingly a story of what’s beginning to work, and what may come next.